


Volume 88
Number 3
Pages 627-956



A Multiplex Urine Biomarker Analysis for Early Detection of Prostate Cancer
Page 645



Stromal Fibroblasts Promote Pancreatic Tumor Progression
Page 918




16-Kinase Gene Expression Identifies Luminal Breast Cancers with Poor Prognosis
Page 767



Cancer Research



PROPERTY OF THE
NATIONAL
LIBRARY OF
MEDICINE



Genome & Co. v. Univ. of Chicago
PGR2019-00002
UNIV. CHICAGO EX. 2026

AACR Officers

William N. Hait, President
Raymond N. DuBois,
President-Elect
Bayard D. Clarkson, Treasurer
Geoffrey M. Wahl, Past President
Margaret Foti,
Chief Executive Officer and
Managing Editor

Publications Committee

Michael A. Caligiuri, Chairperson
Ann F. Chambers
Bayard D. Clarkson
Yves A. De Clerck
Glen Dranoff
Raymond N. DuBois
D. Gary Gilliland
Joe W. Gray
Susan Band Horwitz
David J. Hunter
V. Craig Jordan
Kenneth W. Kinzler
Michelle M. Le Beau
Leroy Fong Liu
Luis F. Parada
David R. Parkinson
Ramon Parsons
Louis M. Staudt
Steven R. Tannenbaum
Cheryl L. Willman
George D. Yancopoulos

Publishing and Editorial Staff, Cancer Research

Publisher: Kathleen Case
Editorial Director:
J. Heather Cullen
Asst. Director, Editorial Systems & Journal Manager:
Kelly A. Hadsell
Production Manager:
Morgan M. Robinson
Production Editors:
Kristin D. Murray
Jeremy Rosenberg
Staff Assistant:
Shira Carroll
Editorial Associates:
Crystal Chetepudom
Mike Williams
Editorial Assistants:
Kathleen Jasion
Kyle A. Overturf
Naima D. Stone
Special Issues Editor:
Diane M. Marinelli
Associate Director,
Electronic Publishing:
Michael Beveridge
Electronic Publishing Specialist:
Mary Beth Cunney
Graphics Director:
Paul Driscoll
Advertising Production:
Susan Moore
Marketing Director:
Jeremy Thompson
Circulation: Karola Rac
Site Licensing: Robert Bergiven

Publishing Information

Cancer Research [ISSN 0008-5472 • CNREA8] is published twice a month, one volume per year, by the AACR, Inc. Periodicals postage paid at Philadelphia, PA, and additional mailing offices. POSTMASTER: Send address changes to: AACR, 615 Chestnut St., 17th Floor, Philadelphia, PA 19106-4404. Printed on acid-free paper in the United States of America.

Submission of Manuscripts

Online submission of new manuscripts is available at <http://can.msubmit.net>. Until January 31, 2008, revisions of manuscripts with numbers lower than CAN-07-5000 must be submitted at <http://www.rapidreview.com/AACR2/author.html>. Beginning February 1, 2008, revisions of manuscripts with numbers lower than CAN-07-5000 must be uploaded as new submissions at <http://can.msubmit.net> and must include a copy of the previous decision letter and comments as supplemental data. Complete submission instructions and further information on the journal's scope and publication policies are available in the Information for Authors at <http://cancerres.aacrjournals.org>, and authors are strongly encouraged to review this information prior to submission.

Manuscript Processing Fee

Journal policy requires that a manuscript fee of \$75 be assessed for each paper to defray the expenses incurred in the editorial review process. This fee is nonrefundable and is levied regardless of the decision rendered on the paper. Upon completion of the online submission process, authors will be directed to a secure site for remitting payment via credit card. Authors who are unable to pay by credit card at the time of submission must contact Ms. Jeri Williams of the AACR Finance office at jeri.williams@aacr.org to make other arrangements. Manuscripts will not enter the review process until the submission fee has been paid.

Page Charges

Accepted manuscripts will be published with the understanding that the author(s) will pay a charge of \$85 per printed page for articles one to six pages in length; \$115 per additional page.

Subscription Information

Subscriptions include online access. Except for members of the AACR, all subscriptions are available to

to AACR Subscription office. The address to which all business communication, remittances (in United States currency or its equivalent), and subscription orders should be sent: Turpin Distribution, (North American Office), 'The Bleachery', 143 West Street, New Milford, CT 06776 [Phone: (860) 350-0041; Fax: (860) 350-0039; or E-mail: turpinNA@turpin-distribution.com]; or (UK Main Office), Pegasus Drive, Stratton Business Park, Biggleswade, Bedfordshire SG18 8TQ, United Kingdom [Phone: (44) 0-1767-604-957; Fax: (44) 0-1767-601-640; or E-mail: custserv@turpin-distribution.com]. In Japan, send orders and inquiries to: USACO Corporation, usaco@usaco.co.jp; Swets Japan, info@jp.swets.com; EBSCO Japan, Japan@ebSCO.com. Individuals who are not AACR members may subscribe to Volume 68 (2008) of Cancer Research at the rate of \$760 U.S./\$900 foreign. Cancer Research is only available to institutions as a combined subscription with Clinical Cancer Research. (Foreign subscription cost includes cost of surface mail. For faster delivery, expedited mailing rates are available by contacting the AACR Publications department.) Canadian subscribers should add 7% GST. Changes of address notification should be sent 60 days in advance and include both old and new addresses. Member subscribers should send address changes to: AACR Member Services, 615 Chestnut St., 17th Floor, Philadelphia, PA 19106-4404. Nonmember subscribers should send changes of address to: AACR Subscription office (aforementioned address). Copies of the journal which are undeliverable because of address changes will be destroyed.

Claims for missing issues made within 90 days of the issue date will be honored while supplies last. Institutions and nonmember individuals, contact AACR Subscription office at the aforementioned address. AACR members, contact AACR Member Services department. Phone: (215) 440-9300; Fax: (215) 440-9412; E-mail: membership@aacr.org.

Single issues copies and copies of back stock of the journal may be ordered from the AACR Subscription office (see "Subscription Information"). Prices are available

Advertisements in Cancer Research

Advertisement insertion orders and copy must be received approximately five weeks prior to the date of the issue in which the advertisement is to be published. Inquiries about advertising should be directed to: M. J. Mrvica Associates, Inc., 2 West Taunton Avenue, Berlin, NJ 08009; Phone: (856) 768-9360; Fax: (856) 753-0064.

Copyright and Permissions

All authors who wish to publish in Cancer Research must formally transfer copyright to the American Association for Cancer Research, Inc., using the release form available at www.aacrsmartssubmit.org. It is understood by this transfer that the authors relinquish all exclusive rights of copyright ownership, including the rights of reproduction, derivation distribution, sale, and display.

Authors who prepared their articles as part of their official duties as employees of the U.S. Federal government are not required to transfer copyright to the AACR, Inc., since these articles are considered to be in the public domain. However, it is necessary for these authors to sign the appropriate section of the transfer form. In the case of articles supported by federal grants or contracts, copyright transfer to AACR, Inc., is required. The federal government may retain a nonexclusive license to publish or republish such material.

Further information on the journal's Copyright and Permissions policy, including instructions on how to request permission to reproduce articles, or portions of articles, is available at <http://www.aacr.org/home/scientists/publications-of-the-aacr/copyright-and-permissions-policy.aspx>.

Cancer Research is abstracted or indexed in Biological Abstracts, Biochemistry & Biophysics Citation Index, Basic BIOSIS, BIOSIS Previews (R) Database, Chemical Abstracts, Index Medicus, MEDLINE, Current Contents/Clinical Medicine, Reference Update, and Science Citation Index (expanded).

No responsibility is accepted by the Editors or by AACR, Inc. for the opinions expressed by contributors or for the content of the advertisements. Copyright 2008 by the American

Cancer Research

A Journal of the American Association for Cancer Research

Volume 68 • Number 3

February 1, 2008 • Pages 627–956

Reviews

- Human Leukocyte Antigen–G and Cancer Immunoediting.** Mirjana Urošević and Reinhard Dummer627
- Targeting the Eukaryotic Translation Initiation Factor 4E for Cancer Therapy.** Jeremy R. Graff, Bruce W. Konicek, Julia H. Carter, and Eric G. Marcussen631

Meeting Report

- Meeting Report: Innovations in Prostate Cancer Research.** Wadiah Arap, Martin Trepel, Bruce R. Zetter, and Renata Pasqualini635

Priority Reports

- Alterations in Gemin5 Expression Contribute to Alternative mRNA Splicing Patterns and Tumor Cell Motility.** Jong Heun Lee, Christine E. Horak, Chand Khanna, Zhaojing Meng, Li Rong Yu, Timothy D. Veenstra, and Patricia S. Steeg639
- A First-Generation Multiplex Biomarker Analysis of Urine for the Early Detection of Prostate Cancer.** Bharathi Laxman, David S. Morris, Jianjun Yu, Javed Siddiqui, Jie Cao, Rohit Mehra, Robert J. Lonigro, Alex Tsoodikov, John T. Wei, Scott A. Tomlins, and Arul M. Chinnaiyan645

Molecular Biology, Pathobiology, and Genetics

- In vivo Switching of Human Melanoma Cells between Proliferative and Invasive States.** Keith S. Hoek, Ossia M. Eichhoff, Natalie C. Schlegel, Udo Döbbeling, Nikita Kobert, Leo Schaerer, Silvio Hemmi, and Reinhard Dummer650
- Multiple Alternative Splicing Markers for Ovarian Cancer.** Roscoe Klinck, Anne Bramard, Lyna Inkel, Geneviève Dufresne-Martin, Julien Gervais-Bird, Richard Madden, Éric R. Paquet, ChuShin Koh, Julian P. Venables, Panagiotis Prinos, Manuela Jilaveanu-Pelms, Raymund Wellinger, Claudine Rancourt, Benoit Chabot, and Sherif About Elela657
- Modeling Genomic Diversity and Tumor Dependency in Malignant Melanoma.** William M. Lin, Alissa C. Baker, Rameen Beroukhi, Wendy Winckler, Whei Feng, Jennifer M. Marmion, Elisabeth Laine, Heidi Greulich, Hsiuyi Tseng, Casey Gates, F. Stephen Hodi, Glenn Dranoff, William R. Sellers, Roman K. Thomas, Matthew Meyerson, Todd R. Golub, Reinhard Dummer, Meenhard Herlyn, Gad Getz, and Levi A. Garraway664
- Tristetraprolin Down-regulates Interleukin-8 and Vascular Endothelial Growth Factor in Malignant Glioma Cells.** Esther Suswam, Yanyan Li, Xiaowen Zhang, G. Yancey Gillespie, Xuelin Li, John J. Shacka, Liang Lu, Lei Zheng, and Peter H. King674
- Spontaneous Squamous Cell Carcinoma Induced by the Somatic Inactivation of Retinoblastoma and Trp53 Tumor Suppressors.** Ana Belén Martínez-Cruz, Mirentxu Santos, M. Fernanda Lara,

TBX3 Is Overexpressed in Breast Cancer and Represses p14^{ARF} by Interacting with Histone Deacetylases. Will Yarosh, Tomasa Barrientos, Taraneh Esmailpour, Limin Lin, Philip M. Carpenter, Kathryn Osann, Hoda Anton-Culver, and Taosheng Huang693

Mitochondrial Cytochrome B Gene Mutation Promotes Tumor Growth in Bladder Cancer. Santanu Dasgupta, Mohammad Obaidul Hoque, Sunil Upadhyay, and David Sidransky700

Cell, Tumor, and Stem Cell Biology

- Enhanced Activation of Epidermal Growth Factor Receptor Caused by Tumor-Derived E-Cadherin Mutations.** Anja Bremm, Axel Walch, Margit Fuchs, Jörg Mages, Justus Duyster, Gisela Keller, Christine Hermannstädter, Karl-Friedrich Becker, Sandra Rauser, Rupert Langer, Claus Hann von Weyhern, Heinz Höfler, and Birgit Lubber707
- CCN3/Nephroblastoma Overexpressed Matricellular Protein Regulates Integrin Expression, Adhesion, and Dissemination in Melanoma.** Viviana Vallacchi, Maria Daniotti, Francesca Ratti, Delia Di Stasi, Paola Deho, Annamaria De Filippo, Gabrina Tragni, Andrea Balsari, Antonino Carbone, Licia Rivoltini, Giorgio Parmiani, Nouredine Lazar, Bernard Perbal, and Monica Rodolfo715
- Modulation of Oncogenic Phenotype in Human Glioma Cells by Cytomegalovirus IE1–Mediated Mitogenicity.** Charles S. Cobbs, Liliana Soroceanu, Scott Denham, Wenyue Zhang, and Matthias H. Kraus724
- Tumor Cell–Secreted Caveolin-1 Has Proangiogenic Activities in Prostate Cancer.** Salahaldin A. Tahir, Guang Yang, Alexei A. Goltsov, Masami Watanabe, Ken-ichi Tabata, Josephine Addai, El Moataz Abdel Fattah, Dov Kadmon, and Timothy C. Thompson731
- The Tumor Suppressor LKB1 Regulates Lung Cancer Cell Polarity by Mediating cdc42 Recruitment and Activity.** Shumin Zhang, Katherine Schafer-Hales, Fadlo R. Khuri, Wei Zhou, Paula M. Vertino, and Adam I. Marcus740
- The Human Trithorax Protein hASH2 Functions as an Oncoprotein.** Juliane Lüscher-Firzlaff, Isabella Gawlista, Jörg Vervoorts, Karsten Kapelle, Till Braunschweig, Gesa Walsemann, Chantal Rodgarkia-Schamberger, Henning Schuchlantz, Stephan Dreschers, Elisabeth Kremmer, Richard Lilischkis, Christa Cerni, Axel Wellmann, and Bernhard Lüscher749
- Loss of Lkb1 Provokes Highly Invasive Endometrial Adenocarcinomas.** Cristina M. Contreras, Sushma Gurumurthy, J. Marshall Haynie, Lane J. Shirley, Esra A. Akbay, Shana N. Wingo, John O. Schorge, Russell R. Broaddus, Kwok-Kin Wong, Nabeel Bardeesy, and Diego H. Castrillon759
- Sixteen–Kinase Gene Expression Identifies Luminal Breast Cancers with Poor Prognosis.** Pascal Finetti, Nathalie Cervera, Emmanuelle Charafe-Jauffret, Christian Chabannon, Colette Charpin, Max Chaffanet, Jocelyne Jacquemier, Patrice Viens, Daniel Birnbaum, and François Bertucci767
- Genotoxic Stress–Induced Expression of p53 and Apoptosis in**

Contents (Continued)

BCL6 Represses Smad Signaling in Transforming Growth Factor- β Resistance. Degang Wang, Jianyin Long, Fangyan Dai, Min Liang, Xin-Hua Feng, and Xia Lin833

CD43, but not P-Selectin Glycoprotein Ligand-1, Functions as an E-Selectin Counter-Receptor in Human Pre-B-Cell Leukemia NALL-1. Chizu Nonomura, Jiro Kikuchi, Nobutaka Kiyokawa, Hidenori Ozaki, Kanae Mitsunaga, Hidenobu Ando, Akiko Kanamori, Reiji Kannagi, Junichiro Fujimoto, Kazuo Muroi, Yusuke Furukawa, and Mitsuru Nakamura790

ABCG2 Expression and Side Population Abundance Regulated by a Transforming Growth Factor β -Directed Epithelial-Mesenchymal Transition. Liqun Yin, Paola Castagnino, and Richard K. Assoian800

Repression of B-Cell Linker (BLNK) and B-Cell Adaptor for Phosphoinositide 3-Kinase (BCAP) Is Important for Lymphocyte Transformation by Rel Proteins. Nupur Gupta, Jeffrey Delrow, Amar Drawid, Anirvan M. Sengupta, Gaofeng Fan, and Céline Gélinas808

The EGFR-STAT3 Oncogenic Pathway Up-regulates the Eme1 Endonuclease to Reduce DNA Damage after Topoisomerase I Inhibition. Arnaud Vigneron, Erick Gamelin, and Olivier Coqueret815

Experimental Therapeutics, Molecular Targets, and Chemical Biology

Tamoxifen Resistance in Breast Tumors Is Driven by Growth Factor Receptor Signaling with Repression of Classic Estrogen Receptor Genomic Function. Suleiman Massarweh, C. Kent Osborne, Chad J. Creighton, Lanfang Qin, Anna Tsimelzon, Shixia Huang, Heidi Weiss, Mothaffar Rimawi, and Rachel Schiff826

Inhibition of Endoplasmic Reticulum Stress-Induced Apoptosis of Melanoma Cells by the ARC Protein. Li Hua Chen, Chen Chen Jiang, Ralph Watts, Rick F. Thorne, Kelly A. Kiejda, Xu Dong Zhang, and Peter Hersey834

Aggravated Endoplasmic Reticulum Stress as a Basis for Enhanced Glioblastoma Cell Killing by Bortezomib in Combination with Celecoxib or Its Non-Coxib Analogue, 2,5-Dimethyl-Celecoxib. Adel Kardosh, Encouse B. Golden, Peter Pyrko, Jasim Uddin, Florence M. Hofman, Thomas C. Chen, Stan G. Louie, Nicos A. Petasis, and Axel H. Schönthal843

Tamoxifen Stimulates the Growth of Cyclin D1-Overexpressing Breast Cancer Cells by Promoting the Activation of Signal Transducer and Activator of Transcription 3. Yuki Ishii, Samuel Waxman, and Doris Germain852

Immunology

Prostate Stem Cell Antigen Vaccination Induces a Long-term Protective Immune Response against Prostate Cancer in the Absence of Autoimmunity. Maria de la Luz Garcia-Hernandez, Andrew Gray, Bolyn Hubby, Otto J. Klingler, and W. Martin Kast861

Tumor-Induced Senescent T Cells with Suppressor Function: A Potential Form of Tumor Immune Evasion. Carolina L. Montes, Andrei I. Chapoval, Jonas Nelson, Vbenosa Orhue, Xiaoyu Zhang, Dan H. Schulze, Scott E. Strome, and Brian R. Gastman870

Systematic High-Content Proteomic Analysis Reveals Substantial Immunologic Changes in Colorectal Cancer. Uta Berndt, Lars Philipsen, Sebastian Bartsch, Bertram Wiedenmann, Daniel C. Baumgart, Marcus Hämmerle, and Andreas Sturm880

Epitope Landscape in Breast and Colorectal Cancer. Neil H. Segal, D. Williams Parsons, Karl S. Peggs, Victor Velculescu, Ken W. Kinzler, Bert Vogelstein, and James P. Allison889

Self-Tolerance Does Not Restrict the CD4+ T-Helper Response against the p53 Tumor Antigen. Marjolein M. Lauwen, Sander Zwaveling, Linda de Quartel, S. Carmela Ferreira Mota, Janine A.C. Grashorn, Cornelis J.M. Melief, Sjoerd H. van der Burg, and Rienk Offringa893

Induction of EBV-Latent Membrane Protein 1-Specific MHC Class II-Restricted T-Cell Responses against Natural Killer Lymphoma Cells. Hiroya Kobayashi, Toshihiro Nagato, Miki Takahara, Keisuke Sato, Shoji Kimura, Naoko Aoki, Makoto Azumi, Masatoshi Tateno, Yasuaki Harabuchi, and Esteban Celis901

Endocrinology

DR5 Receptor Mediates Anoikis in Human Colorectal Carcinoma Cell Lines. Luciana M. Laguinge, Raed N. Samara, Wenge Wang, Wafik S. El-Deiry, Georgia Corner, Leonard Augenlicht, Lopa Mishra, and J. Milburn Jessup909

Clinical Research

Cancer-Associated Stromal Fibroblasts Promote Pancreatic Tumor Progression. Rosa F. Hwang, Todd Moore, Thiruvengadam Arumugam, Vijaya Ramachandran, Keith D. Amos, Armando Rivera, Baoan Ji, Douglas B. Evans, and Craig D. Logsdon918

Epidemiology

Tumor Immunobiological Differences in Prostate Cancer between African-American and European-American Men. Tiffany A. Wallace, Robyn L. Prueitt, Ming Yi, Tiffany M. Howe, John W. Gillespie, Harris G. Yfantis, Robert M. Stephens, Neil E. Caporaso, Christopher A. Loffredo, and Stefan Ambs927

Prevention

Direct Evidence for Epithelial-Mesenchymal Transitions in Breast Cancer. Anthony J. Trimboli, Koichi Fukino, Alain de Bruin, Guo Wei, Lei Shen, Stephan M. Tanner, Nicholas Creasap, Thomas J. Rosol, Michael L. Robinson, Charis Eng, Michael C. Ostrowski, and Gustavo Leone937

Raf and MEK Protein Kinases Are Direct Molecular Targets for the Chemopreventive Effect of Quercetin, a Major Flavonol in Red Wine. Ki Won Lee, Nam Joo Kang, Yong-Seok Heo, Evgeny A. Rogozin, Angelo Pugliese, Mun Kyung Hwang, G. Tim Bowden, Ann M. Bode, Hyong Joo Lee, and Zigang Dong946

Corrections

Correction: SNAI1 Silencing and Inhibition of Breast Tumor Growth956

Correction: IFN Signaling in Aggressive Fibromatosis956

Correction: RPS27L Modulates DNA Damage Response956

Epitope Landscape in Breast and Colorectal Cancer

Neil H. Segal,^{1,2} D. Williams Parsons,⁴ Karl S. Peggs,^{2,3} Victor Velculescu,¹
Ken W. Kinzler,⁴ Bert Vogelstein,⁴ and James P. Allison^{2,3}

¹Department of Medicine, ²Ludwig Center for Cancer Immunotherapy, and ³Immunology Program, Memorial Sloan-Kettering Cancer Center, New York, New York; and ⁴Ludwig Center for Cancer Genetics and Therapeutics at The Johns Hopkins Kimmel Cancer Center, Baltimore, Maryland

Abstract

The finding that individual cancers contain many mutant genes not present in normal tissues has prompted considerable interest in the cancer epitope landscape. To further understand such effects, we applied *in silico*-based epitope prediction algorithms and high throughput post hoc analysis to identify candidate tumor antigens. Analysis of 1,152 peptides containing missense mutations previously identified in breast and colorectal cancer revealed that individual cancers accumulate on average ~10 and ~7 novel and unique HLA-A*0201 epitopes, respectively, including genes implicated in the neoplastic process. These data suggest that, with appropriate manipulation of the immune system, tumor cell destruction *in situ* may provide a polyvalent tumor vaccine without a requirement for knowledge of the targeted antigens. [Cancer Res 2008;68(3):889–92]

Introduction

Several classes of tumor antigens have been described and named according to their distribution in normal and neoplastic tissues. These include the shared differentiation antigens, such as melan-A/MART1 (1, 2) in melanoma; cancer testes or germ cell antigens, such as MAGE-1 (3) and NY-ESO-1 (4) in adult testes and diverse tumor types; and unique tumor antigens, which generally carry mutations, such as CDK4 in melanoma (5) and CASP-8 in head and neck cancer (6).

The immunogenicity of the unique tumor antigens was recognized in several seminal studies including animal transplant models (7) and chemically or UV light-induced tumors (8, 9). They are of particular interest because they result from somatic mutations in individual tumors and are absent from normal tissues (10, 11), providing antitumor specificity without anticipated deleterious autoimmunity. Somatic mutations can be classified as either “drivers” or “passengers”. Passenger mutations provide no positive or negative selective advantage to the tumor but are retained by chance during cell division and clonal expansion. In contrast, driver mutations provide a selective advantage that promotes the tumorigenic process. The generation of mutations is continuous due to the imperfect nature of DNA replication and repair. Thus, the generation of additional antigens during tumor progression, whether driver or passenger (12), provides a continuously renewable source of antigen.

Recent analyses of breast and colorectal cancers showed a remarkable number of somatic mutations in human cancer (13).

Among >13,000 genes analyzed, a total of 1,307 somatic mutations were identified in 11 breast and 11 colorectal cancers. Approximately 83% were missense mutations, 6% nonsense, and the remainder were insertions, deletions, duplications, and changes in noncoding regions. When extrapolated to the whole genome, it was calculated that individual tumors harbored an average of ~90 amino acid-altering (i.e., nonsynonymous) mutations. The kind of information available from such large-scale sequencing studies of individual tumors has not heretofore been available but clearly has implications for tumor immunity.

In the current study, we designed an *in silico* approach to examine whether the mutations identified in Sjoblom et al. (13) have the potential to generate novel epitopes that might serve as targets for an immune response. Using epitope prediction algorithms and high throughput post hoc analysis, we found evidence to support the notion that the human tumorigenic process results in the generation of multiple immune targets. Individual breast and colorectal cancers accumulated an average of ~10 and ~7 novel and unique HLA-A*0201 epitopes, respectively; several within genes that may be drivers. These results provide insights into the unique immune profiles of individual tumors with potential clinical relevance.

Materials and Methods

Epitope prediction. Peptide sequences corresponded to missense mutations identified during the discovery phase by Sjoblom et al. (13), flanked by up to 10 amino acids on either side. Concatamers of these peptides were analyzed with several epitope prediction algorithms for HLA-A*0201 binders. Major histocompatibility complex (MHC)-I antigenic peptide processing prediction (MAPP; ref 14), developed at the Max-Planck Institute, facilitates the prediction of epitopes that can bind to MHC class I molecules based on a score calculated for each subsequence. Each amino acid at a specific position within a subsequence is given a value that has been precalculated and stored in static matrices. The precalculation was done either by BIMAS (15) or SYFPEITHI (16). Depending on the algorithm selected, the values were then multiplied (BIMAS) or added (SYFPEITHI) to determine the score for the subsequence. Peptides qualified as positive if they scored ≥ 100 and ≥ 24 , respectively (17, 18). RANKPEP (19) uses specific scoring matrices from sets of peptides known to bind to MHC molecules as the predictor of MHC-peptide binding. Peptides qualified as positive if the percentage optimum was $\geq 50\%$ or higher. NetMHC (20, 21) predicts peptide-MHC binding using artificial neural networks (ANN) and weight matrices. For ANN, used for HLA-A*0201 prediction, peptides scored positive if IC_{50} is ≤ 500 .

Post hoc analysis. First, we searched for unique epitopes within concatamers of wild-type and mutant peptides. Epitopes identified in the “wild-type concatamer” included both true wild-type epitopes and artifacts across the concatenation sites and were removed from further analysis. The “mutant concatamer” was then used to search for remaining epitopes. To ensure that potential mutant epitopes did not span concatenation sites, the “mutant concatamer” used in this confirmatory phase included additional redundant characters spaced between peptides, thereby permitting confirmation of epitopes contained entirely within a mutant

Requests for reprints: James P. Allison, Ludwig Center for Cancer Immunotherapy, Memorial Sloan-Kettering Cancer Center, 415 East 68th Street, Z-1560, New York, NY 10065. E-mail: allisonj@mskcc.org.

©2008 American Association for Cancer Research.
doi:10.1158/0008-5472.CAN-07-3095

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.